

Supplementary Table 1 Treatment information *n* (%)

Colorectal cancer (<i>n</i> = 237)	
5-fluorouracil/Leucovorin/Irinotecan	87 (37)
5-fluorouracil/Leucovorin/Oxaliplatin	52 (22)
Capecitabine/Oxaliplatin	34 (14)
Capecitabine/Cisplatin	21 (9)
Capecitabine/Capecitabine	11 (5)
5-fluorouracil/Leucovorin/Irinotecan/Oxaliplatin	8 (3)
Fluoropyrimidine monotherapy	15 (6)
Cisplatin monotherapy	5 (2)
Irinotecan monotherapy	4 (2)
<i>In combination with:</i>	
Bevacizumab	73 (31)
Cetuximab	37 (16)
Stomach (<i>n</i> = 38)	
Epirubicin/Oxaliplatin/5-fluorouracil	16 (42)
5-fluorouracil/Oxaliplatin	7 (18.5)
5-fluorouracil/Cisplatin	7 (18.5)
Fluoropyrimidine monotherapy	4 (11)
Epirubicin/Cisplatin/5-fluorouracil	2 (5)
Capecitabine /Irinotecan	2 (5)
<i>In combination with:</i>	
Herceptin	7 (18)
Pancreas (<i>n</i> = 36)	
Gemcitabine/Oxaliplatin	18 (50)
Gemcitabine	10 (28)
5-fluorouracil/Oxaliplatin /Irinotecan /Leucovorin	7 (19)
Cisplatin/vinorelbine	1 (3)
Biliary tract (<i>n</i> = 16)	
Gemcitabine/Oxaliplatin	10 (62)
Gemcitabine	6 (38)

Esophagus (<i>n</i> = 15)	
5-fluorouracil/Capecitabine/Oxaliplatin	10 (67)
Oxaliplatin	3 (20)
Fluoropyrimidine monotherapy	2 (13)

Supplementary Table 2 Clinical features of the 32 patients with venous thromboembolism

Sex	Age	Type	ECOG	Stage	VTE	TTE	BMI	KS	HOMA	T2D	Regimen	Bev
F	64	Colon	1	M1	DVT ¹	3.2	33.8	Inter	1.2	NO	Capecitabine	Yes
F	66	Colon	0	T3N1M0	DVT	5.7	19.4	Low	1.3	NO	FOLFOX	No
F	58	Colon	0	M1	DVT ¹	9.0	22.1	Low	1.6	NO	FOLFIRI	Yes
M	66	Colon	2	M1	DVT ¹	1.0	23.2	Inter	1.6	NO	FOLFIRI	No
M	79	Colon	0	M1	EP	8.8	20.9	Low	2.0	NO	FOLFIRI	Yes
F	68	Colon	0	M1	DVT	3.4	22.5	Low	2.2	NO	FOLFIRI	Yes
M	69	Colon	1	M1	DVT ¹	9.3	24.2	Low	2.8	T2D	FOLFIRI	No
M	69	Colon	0	M1	EP	1.3	32.3	Low	3.2	NO	FOLFIRI	Yes
F	59	Colon	0	M1	DVT ¹	0.9	27.3	Low	4.5	NO	FOLFIRI	No
M	67	Colon	0	M1	EP	3.8	23.5	Inter	4.8	NO	FOLFIRI	Yes
F	73	Colon	0	T1N1M0	DVT	1.6	28.7	Inter	7.2	IGT	FOLFOX	No
M	70	Colon	0	M1	DVT ¹	5.9	26.4	Low	7.6	IGT	Capecitabine	Yes
F	62	Colon	0	M1	DVT	0.9	26.6	Low	7.7	T2D	FOLFIRI	Yes
M	72	Colon	0	T3N0M0	DVT	1.2	26.3	Low	8.3	NO	FOLFOX	No
M	75	Colon	0	T3N1M0	DVT	0.5	28.4	Low	10.7	T2D	FOLFIRI-Cetux	No
M	74	Colon	1	M1	EP	7.5	24.6	Inter	10.9	T2D	FOLFIRI	No
F	61	Colon	0	M1	DVT ¹	8.2	34.5	Low	24.1	T2D	FOLFOX	Yes
M	57	Colon	2	M1	EP	1.4	25.4	Low	2.1	NO	FOLFIRI	No
F	84	Colon	2	M1	DVT	0.3	31.4	Low	2.8	NO	Capecitabine	No
F	70	Rectum	0	T3N1M0	DVT	7.3	24.6	Inter	2.6	NO	FOLFOX	No
M	73	Rectum	1	M1	DVT ¹	3.9	25.8	Low	3.1	NO	IRIFAFU	No
M	75	Rectum	0	M1	EP ¹	0.7	27.4	Low	3.3	NO	FOLFIRI	Yes
F	72	Rectum	1	M1	DVT	3.1	28.1	Inter	7.9	T2D	FOLFIRI	Yes
M	77	Rectum	0	T3N1M0	DVT ¹	2.2	23.5	Low	9.9	NO	FOLFOX	No
F	66	Rectum	0	M1	DVT ¹	3.6	29.4	Low	17.4	T2D	FOLFIRI	No
F	74	Esophagus	0	M1	DVT	1.6	31.6	Low	3.9	NO	FOLFOX	No
M	62	Esophagus	0	T3N1M1	DVT	0.3	29.1	Inter	7.1	T2D	EOX	No
F	65	Stomach	0	M1	DVT	3.3	19.1	Inter	3.8	NO	FOLFOX	No

M	76	Stomach	0	T3N1M0	Catheter	9.2	27.2	High	5.3	NO	FOLFIRI	No
M	62	Stomach	0	M1	EP ¹	6.3	23.1	High	9.4	T2D	XELIRI	Yes
F	77	Pancreas	0	T3N1M0	EP ¹	3.3	27.3	Inter	3.5	T2D	FOLFIRINOX	No
M	84	Pancreas	1	M1	Portal ¹	7.7	25.4	Inter	6.4	T2D	Gemcitabine	No
F	66	Pancreas	0	T2N1M0	Portal ¹	2.8	25.8	Inter	13.5	T2D	GemC	No
F	66	Biliary	1	REC	DVT	2.1	28.9	Inter	4.8	NO	GemC	No

¹Asymptomatic. DVT: Deep Vein Thrombosis; PE: Pulmonary Embolism; TTE: Time-to-Event; T2D: Type 2 Diabetes; IGT: Impaired Glucose Tolerance; KS: Khorana score; HOMA: HOmeostasis Model Assessment index; Cetux, cetuximab; GemC: Gemcitabine/cisplatin; FOLFIRI: 5-fluorouracil/Leucovorin/Irinotecan; FOLFOX: 5-fluorouracil/Leucovorin/Oxaliplatin; IRIFAFU: 5-fluorouracil/Leucovorin/Irinotecan; EOX: 5-fluorouracil/Capecitabine/Oxaliplatin; FOLFIRINOX: 5-fluorouracil/Oxaliplatin /Irinotecan /Leucovorin; XELIRI: Capecitabine/Irinotecan.